What Happened?
Shares of telehealth company Hims & Hers Health (NYSE: HIMS) jumped 4.4% in the morning session after the stock's positive momentum continued as the company announced its expansion into the testosterone replacement therapy market by launching a new category in men's health.
The telehealth company is tapping into a large, underserved market, as an estimated 20 million men in the U.S. struggle with low testosterone. The new offerings will initially include compounded enclomiphene, a drug used to treat the condition. Furthermore, Hims & Hers announced an exclusive partnership with Marius Pharmaceuticals to offer KYZATREX®, an FDA-approved oral testosterone medication, starting in 2026. This strategic move marks the company's entry into the fast-growing hormonal health sector, seen as a way to expand its core sexual health franchise, particularly as sales from its weight-loss drugs have recently slowed.
After the initial pop the shares cooled down to $49.55, up 3.7% from previous close.
Is now the time to buy Hims & Hers Health? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Hims & Hers Health’s shares are extremely volatile and have had 95 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was about 23 hours ago when the stock gained 3.8% on the news that the company announced its long-awaited entry into the testosterone replacement therapy market.
Hims & Hers Health is up 96.6% since the beginning of the year, but at $49.55 per share, it is still trading 27.9% below its 52-week high of $68.74 from February 2025. Investors who bought $1,000 worth of Hims & Hers Health’s shares 5 years ago would now be looking at an investment worth $4,517.
Do you want to know what moves the business you care about? Add them to your StockStory watchlist and every time a stock significantly moves, we provide you with a timely explanation straight to your inbox. It’s free and will only take you a second.
